Arvinas, Inc., a biotechnology company focused on targeted protein degradation therapies, announced that new preclinical data for its investigational drug ARV-393 will be presented at the upcoming ...

The poster highlights the potential for ARV-393 to be combined with various standard of care lymphoma treatments. ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC ...

Arvinas, Inc, a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, announced that new preclinical combination data for ARV-393 will be ...

Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies NEW HAVEN, Conn., April 21, 2025 (GLOBE NEWSWIRE) -- Arvinas, ...